BRAFV600E-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma
Authors:
Open Access
- 3 December 2019
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 10 (64) , 6870-6878
Abstract
Oncotarget | https://doi.org/10.18632/oncotarget.27326 M. Herman Chui, Susanne K. Kjaer, Kirsten Frederiksen, Charlotte G. Hannibal, Tian-Li Wang, Russell Vang, Ie-Ming ShihKeywords
This publication has 14 references indexed in Scilit:
- BRAFV600E mutations and immunohistochemical expression of VE1 protein in low‐grade serous neoplasms of the ovaryHistopathology, 2018
- A nationwide study of ovarian serous borderline tumors in Denmark 1978–2002. Risk of recurrence, and development of ovarian serous carcinomaGynecologic Oncology, 2017
- BRAF Mutation Is Associated With a Specific Cell Type With Features Suggestive of Senescence in Ovarian Serous Borderline (Atypical Proliferative) TumorsAmerican Journal of Surgical Pathology, 2014
- A nationwide study of serous “borderline” ovarian tumors in Denmark 1978–2002: Centralized pathology review and overall survival compared with the general populationGynecologic Oncology, 2014
- Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implantsThe Journal of Pathology, 2013
- KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low‐grade serous carcinomaThe Journal of Pathology, 2013
- Low‐grade serous carcinomas of the ovary contain very few point mutationsThe Journal of Pathology, 2011
- Ovarian Serous Tumors of Low Malignant Potential (Borderline Tumors)American Journal of Surgical Pathology, 2005
- Mutations of BRAF and KRAS Precede the Development of Ovarian Serous Borderline TumorsCancer Research, 2004
- Ovarian serous borderline tumors: A critical review of the literature with emphasis on prognostic indicatorsHuman Pathology, 2000